Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment : A Computational Analysis Evidence
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The evolution of the pandemic has burdened the national healthcare systems worldwide and at present, there is no preferred antiviral treatment for COVID-19. Recently, the SARS-Cov-2 protease structure was released that may be exploited in in-silico studies in order to conduct molecular docking analysis.
METHODS: In particular, we compared the binding of twoantimalarial drugs, already in use, (i.e. chloroquine and hydroxychloroquine), which showed some potential clinical effects on COVID-19 patients, using ritonavir, lopinavir and darunavir as positive control tree antiviral recognized compounds.
RESULTS: Our results showed that hydroxychloroquine but not chloroquine exhibited a significant binding activity to the main protease similar to that possessed by protease inhibitors tested for other viral infections.
CONCLUSION: Our data suggest that hydroxychloroquine may exert additional direct antiviral activity compared to chloroquine. In the absence of clinical studies comparing the efficacy of these two compounds, hydroxychloroquine may offer additional effects and may be considered as the first choice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 27(2021), 10 vom: 02., Seite 1323-1329 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ronsisvalle, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-malarial |
|---|
| Anmerkungen: |
Date Completed 24.05.2021 Date Revised 24.05.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612826666201210092736 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318682192 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318682192 | ||
| 003 | DE-627 | ||
| 005 | 20231225165848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612826666201210092736 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318682192 | ||
| 035 | |a (NLM)33302855 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ronsisvalle, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment |b A Computational Analysis Evidence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2021 | ||
| 500 | |a Date Revised 24.05.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: The evolution of the pandemic has burdened the national healthcare systems worldwide and at present, there is no preferred antiviral treatment for COVID-19. Recently, the SARS-Cov-2 protease structure was released that may be exploited in in-silico studies in order to conduct molecular docking analysis | ||
| 520 | |a METHODS: In particular, we compared the binding of twoantimalarial drugs, already in use, (i.e. chloroquine and hydroxychloroquine), which showed some potential clinical effects on COVID-19 patients, using ritonavir, lopinavir and darunavir as positive control tree antiviral recognized compounds | ||
| 520 | |a RESULTS: Our results showed that hydroxychloroquine but not chloroquine exhibited a significant binding activity to the main protease similar to that possessed by protease inhibitors tested for other viral infections | ||
| 520 | |a CONCLUSION: Our data suggest that hydroxychloroquine may exert additional direct antiviral activity compared to chloroquine. In the absence of clinical studies comparing the efficacy of these two compounds, hydroxychloroquine may offer additional effects and may be considered as the first choice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-malarial | |
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a computational analysis | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a protease inhibitor | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Panarello, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Di Mauro, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardini, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Volti, Giovanni Li |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarella, Giuseppina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 27(2021), 10 vom: 02., Seite 1323-1329 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:10 |g day:02 |g pages:1323-1329 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612826666201210092736 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 10 |b 02 |h 1323-1329 | ||